General Poster SectionsSaturday June 4, 2:00 p.m. to 6:00 p.m. CT, Hall A Abstract No. 7056: BRCA1 mRNA expression patterns in a large lung cancer cohort. In lung cancer, low expression of the DNA repair gene ERCC1 is associated with platinum responsiveness. Expression of a second important DNA repair gene, BRCA1, was quantified in NSCLC tumor samples to determine potential regulatory relationships between the genes and to tumor histology and patient demographics. Of the 425 tumor specimens tested, no association was observed between either gene and patient age or gender. A significant association with histology, however, was identified – media BRCA1 gene expression was higher in squamous cell versus adenocarcinoma (2.39 versus 0.57; P<0.0001). A small but statistically significant positive correlation was also seen between BRCA1 and ERCC1 expression (P<0.001). Monday June 6, 8:00 a.m. to noon CT., Hall A Abstract No. 3053: Integrated research platform (iGXT) for enhancing drug development and personalizing cancer therapy: Pilot study results. A unique approach was taken to test the feasibility of integrating data derived from multiple research models to optimize drug development and treatment strategies. Preclinical data from two mouse models – one possessing tumors with defined EGFR-related characteristics and a second hosting NSCLC patient-derived xenografts – were tested for molecular targets of interest. Information from these and other sources were used to validate the approach and to extrapolate back to individual patient information. Findings from this study may help advance understanding of intra-patient tumor differences to improve personalized cancer therapy. About Response Genetics, Inc. Response Genetics, Inc. (“RGI”) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. RGI was founded in 1999, and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com. Forward-Looking Statement Notice Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the ability of the Company to expand its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric panels, the potential of using the results of this research to be included in cancer care guidelines, the usefulness of genetic information to tailor treatment to patients, the usefulness of gene profiling as a predictor of response to chemotherapy in lung, gastric and colorectal cancers, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.